Regulation of phospholipase D (PLD) in growth plate chondrocytes by 24R,25-(OH)2D3 is dependent on cell maturation state (resting zone cells) and is specific to the PLD2 isoform  by Sylvia, V.L et al.
Regulation of phospholipase D (PLD) in growth plate chondrocytes by
24R,25-(OH)2D3 is dependent on cell maturation state (resting zone cells)
and is speci¢c to the PLD2 isoform
V.L. Sylvia a, Z. Schwartz a;b;c, F. Del Toro a;d, P. DeVeau a;e, R. Whetstone a,
R.R. Hardin a, D.D. Dean a, B.D. Boyan a;b;f ;*
a Department of Orthopaedics, University of Texas Health Science Center at San Antonio, Mail Code 7774, 7703 Floyd Curl Drive,
San Antonio, TX 78229-3900, USA
b Department of Periodontics, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
c Department of Periodontics, Hebrew University Hadassah Faculty of Dental Medicine, Jerusalem 91010, Israel
d Department of Orthodontics, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
e Department of Periodontics, Wilford Hall Medical Center, Lackland Air Force Base, San Antonio, TX 78236, USA
f Department of Biochemistry, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
Received 13 June 2000; received in revised form 17 October 2000; accepted 19 October 2000
Abstract
Many of the effects of 1K,25-(OH)2D3 and 24R,25-(OH)2D3 on costochondral chondrocytes are mediated by the protein
kinase C (PKC) signal transduction pathway. 1K,25-(OH)2D3 activates PKC in costochondral growth zone chondrocytes
through a specific membrane receptor (1K,25-mVDR), involving rapid increases in diacylglycerol via a phospholipase C
(PLC)-dependent mechanism. 24R,25-(OH)2D3 activates PKC in resting zone chondrocytes. Although diacylglycerol is
increased by 24R,25-(OH)2D3, PLC is not involved, suggesting a phospholipase D (PLD)-dependent mechanism. Here, we
show that resting zone and growth zone cells express mRNAs for PLD1a, PLD1b, and PLD2. Both cell types have PLD
activity, but levels are higher in resting zone cells. 24R,25-(OH)2D3, but not 24S,25-(OH)2D3 or 1K,25-(OH)2D3, stimulates
PLD activity in resting zone cells within 3 min via nongenomic mechanisms. Neither 1K,25-(OH)2D3 nor 24R,25-(OH)2D3
affected PLD in growth zone cells. Basal and 24R,25-(OH)2D3-stimulated PLD were inhibited by the PLD inhibitors
wortmannin and EDS. Inhibition of phosphatidylinositol 3-kinase (PI 3-kinase), PKC, phosphatidylinositol-specific PLC
(PI-PLC), and phosphatidylcholine-specific PLC (PC-PLC) had no effect on PLD activity. Thus, 24R,25-(OH)2D3 stimulates
PLD, and PI 3-kinase, PI-PLC and PKC are not involved, whereas PLD is required for stimulation of PKC by 24R,25-
(OH)2D3. Pertussis toxin, GDPLS, and GTPQS had no effect on 24R,25-(OH)2D3-dependent PLD when added to cell
cultures, indicating that G-proteins are not involved. These data show that PKC activation in resting zone cells is mediated
by PLD and suggest that a functional 24R,25-(OH)2D3-mVDR is required. The results also support the conclusion that the
24R,25-(OH)2D3-responsive PLD is PLD2, since this PLD isoform is G-protein-independent. ß 2001 Elsevier Science B.V.
All rights reserved.
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1. Introduction
Rat costochondral resting zone and growth zone
chondrocyte cultures have been used to understand
the di¡erentiation and regulation of cartilage cells
during endochondral development [1,2]. Resting
zone chondrocytes have proven to be an excellent
model for studying the e¡ects of 24R,25-(OH)2D3
because they respond preferentially to this vitamin
D metabolite [3^6]. Conversely, growth zone chon-
drocytes are well suited for studying the response to
1K,25-(OH)2D3 [3]. Each of these metabolites inhibits
chondrocyte proliferation and also plays a role in
stimulating the di¡erentiation and maturation of its
respective target cell.
The costochondral chondrocytes are also an excel-
lent model for studying rapid actions of vitamin D
metabolites. 24R,25-(OH)2D3 regulates arachidonic
acid turnover [7,8] and metabolism [9], as well as
calcium ion £ux [4], membrane £uidity [10] and pro-
tein kinase C (PKC) activity, speci¢cally PKCK
[11,12], in the resting zone cells. The e¡ect of
24R,25-(OH)2D3 on PKC is stereospeci¢c; 24S,25-
(OH)2D3 has no e¡ect [13]. In growth zone cells,
these parameters are regulated by 1K,25-(OH)2D3.
Many of the physiological responses of the chon-
drocytes to the vitamin D metabolites involve PKC-
dependent signaling [1,14]. PKCK is one member of a
family of serine-threonine kinases known to be in-
volved in cell growth and di¡erentiation and whose
activity is regulated by diacylglycerol (DAG) and
calcium [15,16]. Previously, we demonstrated that
1K,25-(OH)2D3 stimulates PKC activity in growth
zone chondrocytes via a phosphatidylinositol-speci¢c
phospholipase C (PI-PLC)-dependent mechanism
that generates DAG and inositol 1,4,5-trisphosphate
[17]. DAG, once formed, binds to and activates PKC
[18]. PKC speci¢c activity is increased by 3 min and
is maximal at 9 min in growth zone cells treated with
1K,25-(OH)2D3.
In resting zone cells, 24R,25-(OH)2D3 also causes
a rapid increase in PKC [19], but maximal increases
in activity are delayed in comparison with the e¡ects
of 1K,25-(OH)2D3 on PKC in growth zone cells [17].
DAG is generated in response to 24R,25-(OH)2D3,
with peak increases coinciding with the peak in
PKC; however, the mechanism involved is independ-
ent of PI-PLC [19].
DAG can also be produced via the action of phos-
pholipase D (PLD) [20,21]. PLD catalyzes the release
of the polar head group from membrane phospho-
lipids, resulting in the formation of phosphatidic
acid. Phosphatidic acid can be further metabolized,
producing lysophosphatidic acid via the action of
phospholipase A2, or DAG via the action of phos-
phatidic acid phosphatase. These PLD-dependent
events play roles in signal transduction of a variety
of hormones, growth factors, cytokines, and neuro-
transmitters (for reviews, see [22^26]). Recent studies
using speci¢c inhibitors of PLD indicate that many
of the physiological responses of resting zone chon-
drocytes to 24R,25-(OH)2D3 that are mediated by
PKC are also mediated by PLD [27], supporting
the hypothesis that there is an interrelationship be-
tween these two signaling pathways. These studies
also suggested that PLD acted upstream from
PKC. Since PLD results in DAG production, and
DAG is the major endogenous regulator of PKC
[18], PLD is an excellent candidate for mediating
the e¡ects of 24R,25-(OH)2D3 on PKC.
Two separate genes, PLD1 and PLD2, encode the
PLD enzyme. PLD1 encodes the 124 kDa protein
PLD1a, and an alternatively spliced form PLD1b,
which lacks 38 amino acids [23,28]. PLD2 encodes
a 106 kDa protein with 50% homology to PLD1 [29].
Mammalian PLD uses phosphatidylcholine exclu-
sively as its substrate, while bacterial and yeast
PLD also use phosphatidylserine, phosphatidyletha-
nolamine and sphingomyelin as substrates [30].
PLD1 has low basal activity and is associated with
the small G-proteins ADP-ribosylation factor (ARF)
and Rho [31]. PLD2 has high basal activity which is
G-protein independent [32].
This study was based on the hypothesis that PLD
is present in both resting zone and growth zone
chondrocytes, but it is regulated only by 24R,25-
(OH)2D3 and only in resting zone cells. We assessed
PLD expression by reverse transcriptase-polymerase
chain reaction (RT-PCR) and Northern analysis.
PLD activity was measured using a polar head group
release assay. We examined whether the e¡ects of
24R,25-(OH)2D3 on resting zone cells and 1K,25-
(OH)2D3 on growth zone cells are mediated by
PLD and determined which type of PLD participates
in the process. To elucidate the mechanism of action
of the vitamin D3 metabolites on PLD, we treated
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resting zone cells with 24R,25-(OH)2D3, or growth
zone cells with 1K,25-(OH)2D3, in the presence of
inhibitors of various signaling pathways and mea-
sured changes in PLD activity.
2. Experimental procedures
2.1. Reagents
1K,25-(OH)2D3 and 24R,25-(OH)2D3 were pur-
chased from Biomol Research Laboratories (Ply-
mouth Meeting, PA); 24S,25-(OH)2D3 was a gift
from Dr. Anthony W. Norman (University of Cali-
fornia, Riverside, CA). Stock solutions were pre-
pared in absolute ethanol and diluted by at least
1/5000 (v/v) with culture medium before addition to
the cultures. PKC assay reagents were obtained from
Gibco (Gaithersburg, MD). D-erythro-Dihydrosphin-
gosine (EDS), U73122, D609, LY294002, chelery-
thrine, GDPLS, GTPQS, pertussis toxin, actinomycin
D and cycloheximide were obtained from Calbio-
chem (San Diego, CA). Wortmannin was obtained
from Alexis (San Diego, CA). Dipalmitoylphospha-
tidylcholine (DPPC) was obtained from Avanti Polar
Lipids (Alabaster, AL). The protein content of each
sample was determined using the bicinchoninic acid
(BCA) protein assay reagent [33] obtained from
Pierce (Rockford, IL). L-K-1-Palmitoyl-2-[14C-arach-
idonyl]phosphatidylcholine was obtained from NEN-
DuPont (Boston, MA).
2.2. Chondrocyte cultures
The culture system has been previously described
in detail [3]. Chondrocytes were obtained from the
resting zone (reserve zone) and the prehypertrophic
and upper hypertrophic zones (growth zone) of cost-
ochondral cartilage from 125 g male Sprague-Dawley
rats (approx. 6 weeks old). Cells were cultured for 7^
10 days at 37‡C in Dulbecco’s modi¢ed Eagle’s me-
dium (DMEM) containing 10% fetal bovine serum
(FBS), 1% penicillin-streptomycin, and 50 Wg/ml so-
dium ascorbate in an atmosphere of 5% CO2 and
100% humidity. For all experiments, con£uent, third
passage cultures were subpassaged into 24-well tissue
culture plates and grown to con£uence prior to treat-
ment with vehicle or the appropriate experimental
medium. Previous studies have demonstrated a re-
tention of di¡erential phenotypic markers through
fourth passage, including cell maturation-speci¢c
responses to 1K,25-(OH)2D3 and 24R,25-(OH)2D3
[1,2,5,6].
2.3. Phospholipase D expression
2.3.1. RT-PCR
RT-PCR was used to determine which PLD genes
are expressed by the chondrocytes. Total RNA was
isolated from con£uent, fourth passage cultures of
resting zone and growth zone chondrocytes after ly-
sis of the cells in guanidinium isothiocyanate and
phenol, and puri¢cation of the RNA with oligo(dT)
cellulose (MicroPoly(A) Pure mRNA isolation kit;
Ambion, Austin, TX) according to the manufactur-
er’s instructions. RNA (1 Wg) was reverse-transcribed
using speci¢c antisense primers and the First-strand
cDNA synthesis kit (Pharmacia, Piscataway, NJ).
Following the initial reverse transcription reaction,
the cDNA was ampli¢ed by adding a speci¢c sense
primer and Taq DNA-polymerase (Fisher, Pitts-
burgh, PA). To ensure speci¢city of RT-PCR reac-
tions, a control experiment with inactive RT was also
performed.
PCR-ampli¢ed fragments were size-selected and
puri¢ed from a 1% agarose gel with QIAquick Gel
Extraction kit (Qiagen, Santa Clarita, CA) and se-
quenced by the Center for Advanced DNA Technol-
ogies in the Department of Microbiology at the Uni-
versity of Texas Health Science Center at San
Antonio. Sequences were con¢rmed by direct com-
parison with published rat PLD1a, PLD1b and
PLD2 sequences available in GenBank (accession
No. AB000778, AB000779 and D88672, respectively
[29,34]). In rat kidney and liver RNA samples, l Wg
of total RNA (purchased from Ambion) was used in
reverse transcriptase reactions. Rat primer sequences
were generated from rat sequences (available in Gen-
Bank) and based on primer sequences shown to am-
plify rat PLD cDNAs. The primers were: PLD1
sense, 5P-GGA CGG TGG GAT GAC AAT
GAG-3P (nucleotides (nt) 1633^1654) and antisense,
5P-ATG CGC TGT GGC TTG AGA CTT T-3P (nt
1974^1995). The PLD2 primers were: sense, 5P-ACG
GAC CTC TTT CCC TAT-3P (nt 352^369) and
antisense, 5P-CAG GTA CTT CTG CTT GCT-3P
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(nt 817^834). The expected product sizes were 731
base pairs (PLD1a), 617 base pairs (PLD1b), and
482 base pairs (PLD2). All primers were synthesized
by Genosys Biotechnologies (The Woodlands, TX).
PCR of PLD1 used a MgCl2 concentration of
0.75 mM, denaturation for 30 s at 94‡C, annealing
for 60 s at 61‡C, and extension for 30 s at 72‡C. PCR
of PLD2 used a MgCl2 concentration of 2 mM with
4.5% DMSO, denaturation for 30 s at 94‡C, anneal-
ing for 60 s at 52‡C, and extension for 30 s at
72‡C.
2.3.2. Northern analysis
To quantitate the basal levels for PLD1 and PLD2
mRNAs, we performed Northern blot analysis. For
these experiments, total RNA was isolated from con-
£uent cultures with TRIzol. Total RNA was quanti-
tated spectrophotometrically, separated on a 1% de-
naturing agarose gel and transferred to a positively
charged nylon membrane (Ambion) with the Turbo-
blotter system (Schleicher and Schuell, Keen, NH).
Northern blots were hybridized with PLD1, PLD2,
and GAPDH strippable 32P-labeled anticoding RNA
probes using the NorthernMax kit (Ambion). PLD1
and PLD2 anti-cRNA probes were synthesized from
sequenced RT-PCR products ampli¢ed with modi-
¢ed antisense primers with the T7 promoter sequence
attached to the 5P end of the antisense primers. Anti-
coding RNA probes were synthesized with the Strip-
EZ T7 kit (Ambion). Northern blots were analyzed
with a PhosphorImager (Molecular Dynamics, Sun-
nyvale, CA).
2.4. Assay of phospholipase D activity
After the appropriate incubation time, the cell
layers were harvested by washing with phosphate
bu¡ered saline (PBS) and loosening from the wells
with a sterile cell scraper. The cell layers were then
lysed in solubilization bu¡er (50 mM Tris-HCl, pH
7.5, 150 mM NaCl, 5 mM EDTA, 1 mM phenyl-
methylsulfonyl £uoride, and 1% NP-40) by letting
them stand on ice for 30 min.
Phospholipase D activity was measured in the cell
culture lysates using a modi¢cation of the method
originally described by Brown et al. [35], which is
based upon the phosphodiester cleavage of phospha-
tidylcholine to form phosphatidic acid and choline.
In our modi¢ed method, we use L-K-1-palmitoyl-2-
[14C-arachidonyl]phosphatidylcholine instead of L-K-
dipalmitoyl[choline-methyl-3H]phosphatidylcholine,so
that the radiolabeled product of PLD action will be
more soluble in the organic solvent. The reaction is
stopped with ice cold chloroform:methanol:water
(2:1:0.8 v/v/v) and the radioactivity in the organic
layer counted.
For assay, 50 Wl aliquots of the cell culture lysates
were mixed with 40 Wl of reaction bu¡er con-
taining 50 mM HEPES, 3 mM EGTA, 80 mM
KCl, 1 mM dithiothreitol, 3 mM MgCl2, and 2 mM
CaCl2, pH 7.5. 10 Wl of substrate solution containing
L-K-1-palmitoyl-2-[14C-arachidonyl]phosphatidylcho-
line (50 000 cpm/reaction tube) and 1 WM dipalmi-
toylphosphatidylcholine carrier were added and the
tubes incubated at 37‡C for 60 min. The reaction was
stopped by addition of 0.3 ml of cold chloroform:
methanol:H2O (2:1:0.8), and 100 Wl of the lower
organic phase was added to 10 ml of Ready-Gel
scintillation cocktail (Beckman Coulter, Fullerton,
CA) and the samples counted.
Since we used a modi¢cation of the method de-
scribed by Brown et al. [35], a time course for diges-
tion of the substrate was conducted. Cell layer ly-
sates from control and 24R,25-(OH)2D3-treated
resting zone cell cultures were incubated with the
substrate for 15^90 min. Both types of samples di-
gested the substrate in a time-dependent manner.
Lysates from 24R,25-(OH)2D3-treated cultures di-
gested 370% more substrate per Wg protein than
those from untreated cultures. Since Brown et al.
used a 60 min assay time and our results indicated
that at 60 min the assay was nearly on the linear part
of the curve, we ran all of our assays for 60 min.
2.5. Regulation of phospholipase D activity by
24R,25-(OH)2D3
Con£uent, fourth passage resting zone and growth
zone chondrocytes were incubated in DMEM con-
taining 10% FBS plus either 24R,25-(OH)2D3
(1039^1037 M), 24S,25-(OH)2D3 (1039^1037 M),
1K,25-(OH)2D3 (10310^1038 M), or vehicle. Cultures
were treated for 3, 9, 90, or 270 min, depending on
the particular experiment. These times were chosen
because previous experiments showed that maximal
stimulation of PKC in resting zone cells treated with
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24R,25-(OH)2D3 occurs at 90 min, while maximal
stimulation of PKC in growth zone cells treated
with 1K,25-(OH)2D3 occurs at 9 min. In the resting
zone cells, PKC activity remains elevated for over
270 min and involves both genomic and nongenomic
mechanisms [12,19], suggesting a potential PKC reg-
ulatory cascade in these cells. In growth zone cells,
however, PKC activity returns nearly to baseline by
90 min, and only nongenomic mechanisms are in-
volved [12,17]. In addition, production of DAG in
resting zone cells is maximal at 90 min in response to
24R,25-(OH)2D3, but 1K,25-(OH)2D3 has no e¡ect
[19]. In contrast, 1K,25-(OH)2D3 causes an increase
in DAG production in growth zone cells within
3 min, and maximal increases are seen at 9 min.
24R,25-(OH)2D3 has no e¡ect on DAG production
in these cells [17].
To determine if PLD activity is regulated by
24R,25-(OH)2D3, resting zone cells were treated
with the vitamin D metabolite and PLD activity
measured following addition of speci¢c inhibitors
of the enzyme. Wortmannin, a general inhibitor of
PLD [36^41], was added to the cultures at concen-
trations of 0.1, 1, and 10 WM. Because wortmannin
can also inhibit the production of phosphatidylinosi-
tol 3-phosphate [42], cultures were also incubated
with 10 WM LY294002, an inhibitor of PI 3-kinase
[43]. There have been reports that wortmannin does
not inhibit PLD directly in some systems [44,45].
Therefore, we also examined whether the general
PLD inhibitor, EDS (1, 10, or 100 WM) [46], would
block the ability of 24R,25-(OH)2D3 to stimulate
PLD activity in resting zone cells.
PLC can also hydrolyze the phosphatidylcholine
substrate used in the PLD assay. Therefore, we
tested the e¡ects of inhibitors of PI-PLC and PC-
PLC on 24R,25-(OH)2D3-induced PLD activity.
Resting zone cell cultures were treated with 0.1, 1,
or 10 WM U73122 to block PI-PLC [47] and with 1,
10, or 100 WM D609 to block PC-PLC [48].
To determine if PLD activation is required for the
stimulation of PKC by 24R,25-(OH)2D3, resting
zone cells were treated for 90 min with vehicle or
1037 M 24R,25-(OH)2D3 in the presence of 1, 10,
or 100 WM EDS. After treatment, PKC activity
was measured in cell layer lysates as previously de-
scribed [12].
2.6. Characterization of the signal transduction
pathway responsible for mediating the e¡ect of
24R,25-(OH)2D3 on phospholipase D
2.6.1. Genomic vs. nongenomic regulatory mechanisms
To determine if new gene expression or protein
synthesis is required for 24R,25-(OH)2D3-dependent
stimulation of phospholipase D activity, resting zone
chondrocytes were treated with 1, 10, or 100 WM
actinomycin D to block transcription, or with 1,
10, or 100 WM cycloheximide to block translation,
as described previously [12].
2.6.2. Role of protein kinase C
Phospholipase D1 (PLD1) activity is regulated by
PKC [28], whereas phospholipase D2 (PLD2) activity
is not [31]. To determine if the 24R,25-(OH)2D3-de-
pendent stimulation of PLD activity is PKC-depen-
dent, we cultured resting zone cells as described
above in the presence of 0.01, 0.1, 1, or 10 WM che-
lerythrine, a speci¢c inhibitor of PKC [49], as de-
scribed previously [19]. Chelerythrine inhibits pri-
marily PKCK [16], which is the predominant PKC
isoform present in resting zone cells and has been
shown by us to be the isoform a¡ected by 24R,25-
(OH)2D3 treatment [11].
2.6.3. Role of G-proteins
To determine if PLD activity is regulated by a G-
protein-dependent mechanism, resting zone chondro-
cytes were treated with 1, 10, 100 WM GTPQS, a G-
protein activator, and with 1, 10, or 100 WM GDPLS,
a competitive G-protein inhibitor [50]. Both of the
guanine nucleoside-based e¡ectors have been shown
to be cell permeable and nontoxic to cell cultures
[51^53]. These studies also enabled us to determine
whether PLD1 or PLD2 is the 24R,25-(OH)2D3-re-
sponsive enzyme, since PLD1 is G-protein-depen-
dent, and PLD2 is G-protein-independent [31].
To verify that G-protein-dependent PLD was
present in the cells, resting zone chondrocytes were
treated for 9 min with control medium or medium
containing 1038 M 24R,25-(OH)2D3 and then lysed
with solubilization bu¡er. 50 Wl aliquots of the cell
culture lysates were incubated directly with GTPQS at
a ¢nal concentration of 1, 10, or 100 WM for an
additional 9 or 90 min, and phospholipase D activity
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assayed as described above. In addition, lysates of
control cultures were treated directly with 1037 M
24R,25-(OH)2D3 to determine if this metabolite had
a direct e¡ect on PLD activity.
2.7. Statistical analysis
For each experiment, each data point represents
the mean þ S.E.M. for six individual cultures (cell
layers). Each experiment was repeated two or more
times to ensure the validity of the data. The data
presented are from a single representative experi-
ment. Signi¢cance between groups was determined
by ANOVA and post hoc testing performed using
Bonferroni’s modi¢cation of Student’s t-test for mul-
tiple comparisons. P-values less than 0.05 were con-
sidered signi¢cant.
3. Results
Both resting zone and growth zone chondrocytes
express mRNA for PLD1a and PLD1b (Fig. 1).
PLD1a- and PLD1b-derived primers ampli¢ed their
expected 731 bp and 617 bp cDNA fragments, re-
spectively. Identical bands were present in RNA
from lung tissue. After ampli¢cation and gel electro-
phoresis, the RT-PCR products were isolated, se-
quenced, and con¢rmed to be PLD1a and PLD1b
by comparison with published rat PLD1 sequences.
Additionally, both cell types express mRNA for
PLD2 (Fig. 2). The PLD2-derived primer ampli¢ed
a 482 bp cDNA fragment. An identical band was
present in RNA from lung tissue. As with the PCR
products for PLD1, the PLD2 product was isolated,
sequenced, and con¢rmed to be PLD2 by compari-
Fig. 1. RT-PCR analysis of PLD1 expression in resting zone (RC) and growth zone (GC) chondrocytes. Poly(A)-enriched RNA was
isolated from con£uent, fourth passage cultures and subjected to RT-PCR as described in Section 2. The ampli¢ed fragments were
separated by 1% agarose gel electrophoresis. The 731 bp and 617 bp bands were sequenced and con¢rmed to be cDNA fragments for
PLD1a and PLD1b, respectively. Reactions were carried out in the presence (+) or absence (3) of reverse transcriptase and compared
to PLD1a and PLD1b from lung tissue.
Fig. 2. RT-PCR analysis of PLD2 expression in resting zone (RC) and growth zone (GC) chondrocytes. Poly(A)-enriched RNA was
isolated from con£uent, fourth passage cultures and subjected to RT-PCR as described in Section 2. The ampli¢ed fragments were
separated by 1% agarose gel electrophoresis. The 482 bp band was sequenced and con¢rmed to be the cDNA fragment for PLD2. Re-
actions were carried out in the presence (+) or absence (3) of reverse transcriptase and compared to PLD2 from lung tissue.
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son with the published rat PLD2 sequence. In both
cases, contamination with genomic DNA was ruled
out by conducting the reactions in the absence of
reverse transcriptase.
Northern analysis con¢rmed that PLD1 and PLD2
mRNAs are present in resting zone and growth zone
chondrocytes (data not shown). When normalized to
GAPDH mRNA, levels of PLD1 and PLD2 in rest-
ing zone chondrocytes were comparable to PLD1
mRNA and PLD2 mRNA levels in growth zone
cells. In both cell types, mRNA for PLD1 was con-
sistently 4^6-fold greater than mRNA for PLD2. The
ratio of PLD1/GAPDH mRNA in resting zone cells
was 1.25 and in growth zone cells, 1.01. The ratio of
PLD2/GAPDH mRNA in resting zone cells was 0.18
and in growth zone cells, 0.25.
Phospholipase D speci¢c activity was evident in
both resting zone and growth zone chondrocytes
with 370% higher activity being found in the resting
zone cell cultures (Fig. 3). Wortmannin (Fig. 4A) and
EDS (Fig. 4B) caused dose-dependent decreases in
PLD activity in resting zone cells, con¢rming that
the enzyme activity being measured was PLD. Sim-
ilarly, wortmannin decreased PLD activity in control
cultures of growth zone cells (data not shown). The
e¡ects of vitamin D metabolites on PLD were cell-
speci¢c. Only resting zone cells responded to 24R,25-
(OH)2D3, with an increase in PLD speci¢c activity
(Fig. 5A), whereas 24R,25-(OH)2D3 had no e¡ect on
PLD in growth zone cells (data not shown). More-
over, the regulation of PLD was metabolite-speci¢c,
since 1K,25-(OH)2D3 had no e¡ect on PLD speci¢c
activity in either cell type (data not shown).
The e¡ects of 24R,25-(OH)2D3 on PLD speci¢c
activity of resting zone cells were both dose- and
time-dependent (Fig. 5). 24R,25-(OH)2D3 caused a
Fig. 3. PLD activity in resting zone (RC) and growth zone
(GC) chondrocyte cultures. Each data point is the mean þ
S.E.M. for six cultures in one experiment. In six additional ex-
periments, the results were comparable. *P6 0.05, GC vs. RC
activity.
Fig. 4. E¡ect of wortmannin and EDS on PLD activity in con-
trol and 24R,25-(OH)2D3-treated resting zone (RC) chondro-
cytes. Con£uent, fourth passage RC cells were treated with con-
trol medium or 1038 M 24R,25-(OH)2D3 in the presence or
absence of 0.1, 1, or 10 WM wortmannin (A) or 1, 10, or
100 WM EDS (B) for 90 min. At harvest, the cell layers were
assayed for PLD activity as described in Section 2. Data repre-
sent the mean þ S.E.M. of six cultures. *P6 0.05, treatment
with wortmannin or EDS vs. control; #P6 0.05, treatment with
24R,25-(OH)2D3 vs. control; P6 0.05, treatment with 1 or
10 WM wortmannin vs. 0.1 WM wortmannin.
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260% increase at 1039 M and a 550% increase at
1037 M in cultures treated for 90 min with the
seco-steroid (Fig. 5A). The e¡ects of 24R,25-
(OH)2D3 were evident within 3 min and were max-
imal at 9 min (Fig. 5B). At 90 min, speci¢c activity of
PLD was still elevated in response to 24R,25-
(OH)2D3, but by 270 min, PLD activity had returned
to control levels.
The e¡ect of 24,25-(OH)2D3 was stereospeci¢c
(Table 1). Only 24R,25-(OH)2D3 elicited a dose-de-
pendent increase in PLD speci¢c activity in resting
zone cells.
This increase in enzyme activity in response to
24R,25-(OH)2D3 was completely blocked by the ad-
dition of wortmannin (10 WM) to the cultures, indi-
cating that the increase in enzyme activity was due to
PLD. Moreover, the e¡ects of wortmannin were con-
centration-dependent in the 0.1^1.0 WM range (Fig.
4A). The inhibitory e¡ect of wortmannin on PLD
activity in control cultures, as well as on 24R,25-
(OH)2D3-stimulated PLD activity, was consistently
observed, as indicated by the comparison of treat-
ment/control ratios from seven separate experiments
(data not shown). Similarly, the PLD inhibitor EDS
also blocked the stimulatory e¡ect of 24R,25-
(OH)2D3 on PLD activity and caused a decrease in
basal PLD activity (Fig. 4B). The PI 3-kinase inhib-
itor LY294002 had no e¡ect (data not shown), fur-
ther demonstrating that wortmannin inhibited PLD,
and not PI 3-kinase.
The e¡ect of 24R,25-(OH)2D3 on PKC activity in
resting zone cells was dependent on PLD (Fig. 6).
Inhibition of PLD with EDS decreased PKC speci¢c
activity in control cultures at 100 WM EDS. In con-
trast, in cultures treated with 24R,25-(OH)2D3, EDS
blocked the action of 24R,25-(OH)2D3 on PKC ac-
tivity.
The 24R,25-(OH)2D3-dependent increase in PLD
activity in resting zone cells did not involve PLC
Fig. 5. E¡ect of 24R,25-(OH)2D3 on PLD activity in resting
zone (RC) chondrocytes. Con£uent, fourth passage RC cells
were treated with control medium, 1039, 1038, or 1037 M
24R,25-(OH)2D3 for 90 min in the presence or absence of
10 WM wortmannin (A), or with control medium, 1038 or 1037
M 24R,25-(OH)2D3 for 3, 9, 90, or 270 min (B). At harvest,
the cell layers were assayed for PLD activity as described in
Section 2. Data represent the mean þ S.E.M. of six cultures.
*P6 0.05, treatment with 24R,25-(OH)2D3 vs. control ;
#P6 0.05, treatment with wortmannin vs. no wortmannin (A)
or treatment with 24R,25-(OH)2D3 for 3 or 90 min vs. 9 min
(B).
Table 1
E¡ect of 24S,25-(OH)2D3 and 24R,25-(OH)2D3 on phospholi-
pase D activity in resting zone chondrocytes
Treatment Phospholipase D speci¢c activity
(dpm/Wg protein/h)
9 min 90 min
Control 530 þ 10 580 þ 40
24S,25-(OH)2D3
1039 M 510 þ 30 580 þ 20
1038 M 560 þ 20 560 þ 50
1037 M 540 þ 20 560 þ 40
24R,25-(OH)2D3
1039 M 1700 þ 50* 1470 þ 30*
1038 M 1860 þ 40*2 1680 þ 10*2
1037 M 2000 þ 60*2 1900 þ 40*2
*P6 0.05, vs. control.
2P6 0.05, vs. 1039 M 24R,25-(OH)2D3.
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(data not shown). Neither the PI-PLC inhibitor
U73122, nor the PC-PLC inhibitor D609, had an
e¡ect on control or 24R,25-(OH)2D3-stimulated
PLD activity.
The activation of PLD activity by 24R,25-
(OH)2D3 was independent of either transcription or
translation (data not shown). Actinomycin D had no
e¡ect on PLD activity in control resting zone cells,
nor did it inhibit the activity in 24R,25-(OH)2D3-
treated cultures, either at 9 min or at 90 min of treat-
ment. Likewise, cycloheximide had no e¡ect on PLD
activity in control or 24R,25-(OH)2D3-treated cul-
tures.
24,25-(OH)2D3-stimulated PLD activity was inde-
pendent of PKC. Chelerythrine, a speci¢c PKC in-
hibitor, had no e¡ect on PLD activity in either con-
trol or 24R,25-(OH)2D3-treated cultures at 9 min or
90 min (data not shown).
24R,25-(OH)2D3-dependent PLD activity in rest-
ing zone cells was also independent of G-proteins.
Treatment with pertussis toxin failed to a¡ect en-
zyme activity (data not shown). Similarly, the general
G-protein inhibitor GDPLS had no e¡ect on PLD
activity in either control or 24R,25-(OH)2D3-treated
cultures at 9 min (Fig. 7A). Likewise, the G-protein
activator GTPQS had no e¡ect (Fig. 7B). In addition,
neither GDPLS nor GTPQS had an e¡ect on PLD in
control cultures or cultures treated with 24R,25-
(OH)2D3 for 90 min (data not shown).
Functional G-protein-dependent PLD was present
in the cells, however. GTPQS stimulated PLD activity
in lysates of both control and 24R,25-(OH)2D3-
stimulated cultures (Fig. 8A). The extent of the stim-
ulatory e¡ect in the cultures treated with both
Fig. 6. E¡ect of the PLD inhibitor EDS on PKC speci¢c activ-
ity in resting zone chondrocytes. Con£uent, fourth passage RC
cells were treated with control medium or 1038 M 24R,25-
(OH)2D3 in the presence or absence of 1, 10, or 100 WM EDS
for 9 min. At harvest, cell layers were assayed for PKC activity
as described in Section 2. Data represent the mean þ S.E.M. of
six cultures. *P6 0.05, treatment with EDS vs. no EDS;
#P6 0.05, treatment with 24R,25-(OH)2D3 vs. control.
Fig. 7. E¡ect of G-protein inhibition and activation on PLD
activity in resting zone (RC) chondrocytes treated with 24R,25-
(OH)2D3. Con£uent, fourth passage RC cells were treated for
9 min with control medium or 1038 M 24R,25-(OH)2D3 in the
presence or absence of 1, 10, or 100 WM GDPLS (A) or 1, 10,
or 100 WM GTPQS (B). At harvest, the cell layers were assayed
for PLD activity as described in Section 2. Data represent the
mean þ S.E.M. of six cultures. #P6 0.05, treatment with
24R,25-(OH)2D3 vs. control.
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24R,25-(OH)2D3 and GTPQS was comparable to the
e¡ect observed in the cultures treated with GTPQS
alone. When 24R,25-(OH)2D3 alone was added to
similarly prepared lysates, however, there was no ef-
fect on PLD activity at either 9 or 90 min (Fig. 8B).
4. Discussion
This study demonstrates that PLD is present in
both resting zone and growth zone chondrocytes,
but it is regulated by vitamin D in a metabolite-spe-
ci¢c manner that is strictly dependent on the matu-
ration state of the cell in the endochondral lineage.
The three known isoforms of PLD, PLD1a, PLD1b,
and PLD2, were present in both cell types, although
PLD1 mRNAs were enriched over PLD2 mRNAs in
control cultures. While mRNA levels were compara-
ble in both cell types, resting zone cells exhibited ¢ve
times higher PLD activity than was observed in
growth zone cells. The activity was veri¢ed as PLD
rather than other phospholipases by using an assay
with optimized bu¡er and substrate conditions, and
through the use of two PLD inhibitors. Moreover,
the speci¢city of the inhibitor wortmannin was veri-
¢ed by the use of an inhibitor of its overlapping
activity, PI 3-kinase. Finally, the activity was shown
not to involve PLC through inhibition of both PI-
PLC and PC-PLC.
The inhibitory e¡ects of wortmannin on PLD in
the control cultures also indicate that this enzyme
activity is present in the cells even in the absence of
a regulatory stimulus. Whether inhibition of consti-
tutive PLD caused cell toxicity was not tested di-
rectly. However, the cultures appeared normal by
phase contrast microscopy, and there was no dimin-
ution in the amount of protein in each sample, sug-
gesting that protein synthesis was una¡ected. Inhibi-
tion of PLC, PKC, PI 3-kinase, mRNA production,
or protein synthesis had no e¡ect on the robustness
of the cell response to 24R,25-(OH)2D3, indicating
that cell physiology was una¡ected. Given the rela-
tively short time course of the experiment, it is un-
likely that wortmannin or EDS exerted a toxic e¡ect
on the cells.
The regulation of PLD by the vitamin D metabo-
lites was observed only in resting zone cells and only
in response to 24R,25-(OH)2D3, indicating that it is
both cell maturation-dependent and metabolite-spe-
ci¢c. 1K,25-(OH)2D3 had no e¡ect on this enzyme in
either cell type, nor did 24R,25-(OH)2D3 stimulate
PLD in growth zone cells. Moreover, the e¡ect of
24,25-(OH)2D3 was stereospeci¢c, since 24S,25-
(OH)2D3 had no e¡ect. This suggests that 24R,25-
(OH)2D3 exerts its e¡ects via a receptor-mediated
Fig. 8. Direct e¡ect of GTPQS on PLD activity in resting zone
(RC) chondrocyte lysates. Con£uent, fourth passage RC cells
were treated for 9 min with control medium or 1038 M 24R,25-
(OH)2D3 and lysed in solubilization bu¡er. 50 Wl aliquots of
these cell culture lysates were incubated directly with 1, 10, or
100 WM GTPQS for an additional 9 min, and then assayed for
PLD activity (A) as described in Section 2. In another series of
experiments, fourth passage RC cells were treated for 9 min
with control medium and then lysed as above. 50 Wl aliquots of
these cell culture lysates were incubated directly with 1038 M
24R,25-(OH)2D3 for an additional 9 or 90 min and then as-
sayed for PLD activity (B) as described in Section 2. Data rep-
resent the mean þ S.E.M. of six cultures. *P6 0.05, treatment
with GTPQS vs. control ; #P6 0.05, treatment with 24R,25-
(OH)2D3 vs. control.
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mechanism. In addition, it indicates the importance
of the orientation of the hydroxyl on carbon 24 in
the action of this metabolite on PLD.
The results of this study also suggest that PLD
plays a pivotal role in mediating signal transduction
in resting zone cells, particularly in response to
24R,25-(OH)2D3. Levels of enzyme activity in con-
trol cultures were higher in resting zone cells, and
physiological levels of 24R,25-(OH)2D3 elicited 4^5-
fold increases. This hypothesis is further supported
by the fact that inhibition of PLD activity blocks the
biological e¡ects of 24R,25-(OH)2D3 in resting zone
cells, including stimulation of alkaline phosphatase
speci¢c activity [27].
Related studies in our lab have shown that PKC is
regulated by 24R,25-(OH)2D3 in resting zone cells
via production of diacylglycerol, but neither PLC
[19] nor phospholipase A2 is involved [54]. PLD is
an excellent candidate for PKC activation by 24R,25-
(OH)2D3 [19]. In the present study, inhibition of
PLD resulted in inhibition of PKC, supporting this
hypothesis. Moreover, we showed that PKC inhibi-
tion did not block PLD activity, indicating that PKC
does not act upstream from PLD in 24R,25-
(OH)2D3-treated cells, further demonstrating that
PLD mediates the e¡ect of 24R,25-(OH)2D3 on
PKC, and not vice versa.
We had previously shown that 24R,25-(OH)2D3
stimulates PKC activity in the presence of pertussis
toxin or choleratoxin, inhibitors of Gi- and Gs-pro-
teins, respectively [19], as well as in the presence of
the general inhibitor GDPLS [55]. Therefore, the
question of how PLD is activated was not clear.
Our results indicate that PLD2 is the enzyme form
that is sensitive to 24R,25-(OH)2D3, resolving the
apparent incongruities with our previous observa-
tions. PLD2 is characterized by high basal activity
and acts on PKC independently of G-proteins,
whereas PLD1a and PLD1b are regulated in part
by the small G-protein ARF and by PKC [31]. In
the present study, the 24R,25-(OH)2D3-sensitive
PLD was not a¡ected by the PKC inhibitor cheler-
ythrine. It was also not sensitive to the actions of
GDPLS or GTPQS. The fact that PLD activity in
cell lysates could be stimulated by GTPQS indicates
that functional G-protein is present in the cells and
that PLD1a and PLD1b are present, but they do not
participate in the 24R,25-(OH)2D3 signaling path-
way.
These results also demonstrate that 24R,25-
(OH)2D3 exerts its e¡ects on PLD via a membrane-
mediated mechanism. Addition of 24R,25-(OH)2D3
to cell lysates did not result in increased PLD activ-
ity. Chondrocytes have been reported to have recep-
tors for 24R,25-(OH)2D3 [56], but e¡orts to identify
a nuclear receptor have not been successful [56,57].
The e¡ect of 24R,25-(OH)2D3 on PLD did not re-
quire gene transcription or translation, even at
90 min, supporting the hypothesis that nongenomic
mechanisms are involved. Indeed, mRNAs for PLD2
were present at relatively low levels in the cells under
control conditions. While we did not examine the
e¡ects of 24R,25-(OH)2D3 on mRNA levels, signi¢-
cant stimulation of enzyme activity was evident at
3 min, indicating a rapid response, again supporting
a mechanism that does not involve new mRNA pro-
duction. Moreover, the e¡ect of 24,25-(OH)2D3 was
stereospeci¢c, since 24S,25-(OH)2D3 had no e¡ect.
These observations are consistent with activation
via a membrane receptor speci¢c for 24R,25-
(OH)2D3, as has been described in resting zone chon-
drocytes [58], chick fracture callus [59], and chick
intestinal epithelium [60]. This conclusion is sup-
ported by the fact that 24S,25-(OH)2D3 also has no
e¡ect on PKC in resting zone chondrocytes [13]. Our
results also show that the membrane e¡ect of
24R,25-(OH)2D3 on PLD is not through the
mVDR for 1K,25-(OH)2D3, since this metabolite
had no e¡ect in either resting zone or growth zone
cells.
The speci¢c stimulation of PLD by 24R,25-
(OH)2D3 has important consequences for resting
zone cells. Both resting zone cells and growth zone
cells possess 1,25-mVDRs based on speci¢c binding
of 1K,25-[3H](OH)2D3 to the membrane and immu-
noreactivity to Ab99 [61], but most of the e¡ects of
1K,25-(OH)2D3 on cell di¡erentiation are limited to
growth zone cells. In addition, 1K,25-(OH)2D3 causes
an increase in PKCK activity only in growth zone
cells. In contrast, both cell types exhibit speci¢c
membrane binding to 24R,25-[3H](OH)2D3, but this
metabolite a¡ects primarily resting zone cells [58],
and PKCK is stimulated by 24R,25-(OH)2D3 only
in resting zone cells. The fact that PLD is regulated
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by 24R,25-(OH)2D3 and not 1K,25-(OH)2D3, and the
e¡ect of 24R,25-(OH)2D3 is exclusive to resting zone
cells may account for this speci¢city.
The involvement of PLD in the mechanism of ac-
tion of 24R,25-(OH)2D3 on PKCK also explains the
observed time course on PKC activity noted previ-
ously [19]. 24R,25-(OH)2D3 causes a rapid increase
in activity of existing PKC [12], commensurate with
the rapid increase in PLD activity observed in the
present study. However, PKC activity does not reach
maximal activity until 90 min and remains elevated
over 270 min, and this latter e¡ect requires new gene
expression and protein synthesis [12].
In contrast, the e¡ect of 1K,25-(OH)2D3 on PKC
activity in growth zone cells is maximal within 9 min,
and by 90 min, is resolved. 1K,25-(OH)2D3 exerts its
e¡ect via PLC, resulting in direct production of
DAG. The delayed e¡ect of 24R,25-(OH)2D3 on
DAG production in resting zone cells correlates
with the fact that PLD results in release of phospha-
tidic acid, which must be further metabolized to
DAG. Although regulation of PLD did not require
genomic activity, regulation of PKC does, at least to
achieve maximal response at 90 min. This suggests
that the action of PLD leads to a genomic response,
potentially through a MAP kinase-dependent signal-
ing pathway [62]. By using membrane signaling
mechanisms then, 24R,25-(OH)2D3 can regulate dif-
ferentiation and maturation of resting zone chondro-
cytes even in the absence of nuclear receptors for this
vitamin D metabolite.
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